Accelerate diagnostics, inc. announces presentation of full data from three outcome studies at idweek(tm) 2019

Accelerate diagnostics, inc. announced presentation of full data from three outcome studies at idweek(tm) 2019. the full data being presented build upon the high-level findings. the first of the studies is rapids-gn, a randomized controlled trial conducted at mayo clinic and ucla. rapids-gn focused on gram-negative bacteremia and randomized patients to be tested by the bc kit or legacy methods. the study met the primary endpoint of therapy optimization, reporting time to first gram-negative antibiotic change a full 24 hours sooner than legacy methods (17.4 hours vs. 42.1 hours, p<0.01) and time to any antibiotic change 6 hours sooner (8.6 hours vs. 14.9 hours, p=0.02). a prior study by the mayo clinic was unable to demonstrate any statistically significant differences in similar antibiotic use endpoints for patients with gram-negative bacteremia when using a molecular id-only test (biofire(tm)), highlighting the fact that both rapid id and phenotypic ast are required for physicians to take early, and potentially life-saving, action to adjust antibiotics for these patients. rapids-gn also reported on secondary endpoints such as length of stay (los) and mortality but did not find statistically significant differences. "the study was not powered to detect differences in these outcomes," commented dr. banerjee. "patients in the rapid testing arm were sicker than those in the control arm, which may have biased against seeing a benefit in these outcomes." mayo clinic has among the lowest rates of gram-negative resistant bacteria in the u.s., with a short baseline los of 7.1 days. uams, with a baseline los of 11.9 days as reported at idweek(tm) 2019, was able to reduce los for its patients by over two days to 9.5 days with the accelerate pheno(tm) system with no additional changes to their existing stewardship practices. following review of the data from rapids-gn, mayo clinic purchased the accelerate pheno(tm) system, furthering its investment in antibiotic stewardship and its focus on improving patient care by reducing antibiotic overuse. other institutions like uams and university of iowa, which also reported data on the system at idweek(tm) 2019, also purchased the accelerate pheno(tm) system to bolster their antibiotic stewardship programs and help reduce hospital los. unlike rapids-gn, the university of iowa and uams studies evaluated patients with both gram-positive and gram-negative bloodstream infections. uams specifically reported the different impact of the system for gram-positive and gram-negative patient groups, showing a statistically significant decrease in time on broad-spectrum gram-positive coverage (e.g., vancomycin) of 23.3 hours (p=0.02) and a decrease of time on broad-spectrum gram-negative coverage (e.g., piperacillin-tazobactam) of 38.4 hours (p<0.01) with the accelerate pheno(tm) system. "i find the outcomes of the study to be very exciting.
AXDX Ratings Summary
AXDX Quant Ranking